In this study the concentration of plasma breakdown products of cross-linked fibrin (XDP), serum fibrinogen-fibrin degradation products (FDP), and plasma fibrinogen were measured before and at the end of the administration of single-chain recombinant tissue-type plasminogen activator (rt-PA, 100 mg IV over three hours) or streptokinase (1.5 million units over one hour), respectively, in two groups, each composed of 22 patients with acute myocardial infarction. The XDP concentration was not statistically different between the two groups at the end of thrombolytic treatment, whereas FDP and fibrinogen concentrations were significantly different (FDP: streptokinase 396 ± 287 vs rt-PA 177 ± 222 μg/mL, p < 0.01; fibrinogen: streptokinase 71 ± 43 vs rt-PA 181 ± 49 mg/dL, p < 0.001). These results indicate that the two drugs have equipotent thrombolytic activity at this administration regimen but that rt-PA causes a markedly more selective lysis of fibrin in comparison with streptokinase.
References
1.
Bergmann SR, Fox Kaa, Ter-Pogossian MM, et al: Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science220:1181-11831983.
2.
Elms MJ, Bunce IM, Bundersen PG, et al: Measurement of crosslinked fibrin degradation products—an immunoassay using monoclonal antibodies. Thromb Haemostas50:591-594, 1983.
3.
Whitaker AN, Elms MS, Masci PP, et al: Measurement of cross linked fibrin derivates in plasma: An immunoassay using monoclonal antibodies. J Clin Pathol37:882-887, 1984.
4.
Koppert PW, Hoegee-de Nobel E, Nieuwenhuizen W.: A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemostas59:310-315, 1988.
5.
Verstraete M. , Collen D.: Thrombolytic therapy in the eighties . Blood67:1529-1537, 1986 .
6.
Sobel BE, Gross RW, Robison AK: Thrombolysis, clot selectivity, and kinetics. Circulation70:160-164, 1984.
7.
Topol EJ, Bell WR, Weisfeldt ML: Coronary thrombolysis with recombinant tissue-type plasminogen activator . Ann Intern Med103:837-843, 1985.
8.
Garvey B., Black JM: The detection of fibrinogen/fibrin degradation product by means of a new antibody coated particle. J Clin Pathol25:680-682, 1972.
9.
Vermylen C., DeVreker R., Verstraette M., et al: A quick quantitative enzymatic fibrinogen assay method: The fibrin polymerization time (FPT). Clin Chim Acta8:418-424, 1963.
10.
Lew A., Berberian L., Cercek B., et al: Elevated serum D dimer: A degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction . J Am Coll Cardiol7:1320-1324, 1986 .
11.
Gaffney PJ, Chesterman CN, Allington MJ: Plasma fibrinogen and its fragments during streptokinase treatment . Br J Haematol26:285-293, 1974.
12.
Gaffney PJ, Perry MJ: Unreliability of current serum fibrin degradation product (FDP) assays . Thromb Haemostas53:301-302, 1985.
13.
Gaffney PJ, Creighton LT, Callus M., et al: Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). Br J Haematol68:91-96, 1988.
14.
Rao K., Pratt C., Berke A., et al: Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestation and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol11:1-11, 1988.
